Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption

被引：10

作者：

Barreiro, P ^{[1
]}

de Mendoza, C ^{[1
]}

González-Lahoz, J ^{[1
]}

Soriano, V ^{[1
]}

机构：

[1] Hosp Carlos 3, Dept Infect Dis, Madrid 28029, Spain

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 41卷 / 06期

关键词：

D O I：

10.1086/432887

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Forty-five human immunodeficiency virus (HIV) - infected patients stopped taking treatment but resumed taking it thereafter. All 11 who resumed treatment with their prior protease inhibitor (PI) - based regimen reattained an undetectable virus load, whereas this occurred for only 15 (44%) of 34 patients who resumed nonnucleoside reverse-transcriptase inhibitor (NNRTI) - based treatment (P < .001). Distinct pharmacokinetics and resistance barriers may result in different performances for PIs and NNRTIs after treatment interruptions.

引用

收藏

页码：897 / 900

页数：4

相关论文

共 16 条

[1] Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides [J].

Barreiro, P ;

Soriano, V ;

Casas, E ;

González-Lahoz, J .

AIDS, 2002, 16 (02) :245-249

[2]

Barreiro Pablo, 2002, AIDS Reviews, V4, P233

[3] Higher antiviral activity of antiretroviral regimens including protease inhibitors [J].

de Mendoza, C ;

Soriano, V ;

Rodríguez-Rosado, R ;

González-Lahoz, J .

AIDS, 1999, 13 (08) :998-999

[4] KINETIC CHARACTERIZATION AND CROSS-RESISTANCE PATTERNS OF HIV-1 PROTEASE MUTANTS SELECTED UNDER DRUG PRESSURE [J].

GULNIK, SV ;

SUVOROV, LI ;

LIU, BS ;

YU, B ;

ANDERSON, B ;

MITSUYA, H ;

ERICKSON, JW .

BIOCHEMISTRY, 1995, 34 (29) :9282-9287

[5] Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients [J].

Havlir, DV ;

Eastman, S ;

Gamst, A ;

Richman, DD .

JOURNAL OF VIROLOGY, 1996, 70 (11) :7894-7899

[6] Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission [J].

Jackson, JB ;

Becker-Pergola, G ;

Guay, LA ;

Musoke, P ;

Mracna, M ;

Fowler, MG ;

Mofenson, LM ;

Mirochnick, M ;

Mmiro, F ;

Eshleman, SH .

AIDS, 2000, 14 (11) :F111-F115

[7] Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection [J].

Martinez, E ;

Arnaiz, JA ;

Podzamczer, D ;

Dalmau, D ;

Ribera, E ;

Domingo, P ;

Knobel, H ;

Riera, M ;

Pedrol, E ;

Force, L ;

Llibre, JM ;

Segura, F ;

Richart, C ;

Cortes, C ;

Javaloyas, M ;

Aranda, M ;

Cruceta, A ;

de Lazzari, E ;

Gatell, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11) :1036-1046

[8]

Masquelier B, 2001, J ACQ IMMUN DEF SYND, V28, P309, DOI 10.1097/00126334-200112010-00001

[9]

MELLORS JW, 2004, 11 C RETR OPP INF SA

[10] A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients - The INCAS trial [J].

Montaner, JSG ;

Reiss, P ;

Cooper, D ;

Vella, S ;

Harris, M ;

Conway, B ;

Wainberg, MA ;

Smith, D ;

Robinson, P ;

Hall, D ;

Myers, M ;

Lange, JMA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (12) :930-937